Global PET Radiopharmaceuticals Market Analysis and Forecast 2025-2031
Description
Summary
According to APO Research, The global PET Radiopharmaceuticals market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of PET Radiopharmaceuticals include Cardinal Health Inc. (U.S.), Bayer AG (Germany), Nordion, Inc. (Canada), Mallinckrodt plc (Ireland), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), GE Healthcare (U.K.), Eczacibasi-Monrol Nuclear Products (Turkey) and Bracco Imaging S.p.A (Italy), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for PET Radiopharmaceuticals, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of PET Radiopharmaceuticals, also provides the sales of main regions and countries. Of the upcoming market potential for PET Radiopharmaceuticals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PET Radiopharmaceuticals sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global PET Radiopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for PET Radiopharmaceuticals sales, projected growth trends, production technology, application and end-user industry.
PET Radiopharmaceuticals Segment by Company
Cardinal Health Inc. (U.S.)
Bayer AG (Germany)
Nordion, Inc. (Canada)
Mallinckrodt plc (Ireland)
Lantheus Medical Imaging, Inc. (U.S.)
IBA Molecular Imaging (Belgium)
GE Healthcare (U.K.)
Eczacibasi-Monrol Nuclear Products (Turkey)
Bracco Imaging S.p.A (Italy)
Advanced Accelerator Applications S.A. (France)
PET Radiopharmaceuticals Segment by Type
F-18
Ru-82
Others
PET Radiopharmaceuticals Segment by Application
Neurology
Cardiology
Oncology
Others
PET Radiopharmaceuticals Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PET Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PET Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PET Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of PET Radiopharmaceuticals in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of PET Radiopharmaceuticals manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PET Radiopharmaceuticals sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global PET Radiopharmaceuticals market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of PET Radiopharmaceuticals include Cardinal Health Inc. (U.S.), Bayer AG (Germany), Nordion, Inc. (Canada), Mallinckrodt plc (Ireland), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), GE Healthcare (U.K.), Eczacibasi-Monrol Nuclear Products (Turkey) and Bracco Imaging S.p.A (Italy), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for PET Radiopharmaceuticals, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of PET Radiopharmaceuticals, also provides the sales of main regions and countries. Of the upcoming market potential for PET Radiopharmaceuticals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PET Radiopharmaceuticals sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global PET Radiopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for PET Radiopharmaceuticals sales, projected growth trends, production technology, application and end-user industry.
PET Radiopharmaceuticals Segment by Company
Cardinal Health Inc. (U.S.)
Bayer AG (Germany)
Nordion, Inc. (Canada)
Mallinckrodt plc (Ireland)
Lantheus Medical Imaging, Inc. (U.S.)
IBA Molecular Imaging (Belgium)
GE Healthcare (U.K.)
Eczacibasi-Monrol Nuclear Products (Turkey)
Bracco Imaging S.p.A (Italy)
Advanced Accelerator Applications S.A. (France)
PET Radiopharmaceuticals Segment by Type
F-18
Ru-82
Others
PET Radiopharmaceuticals Segment by Application
Neurology
Cardiology
Oncology
Others
PET Radiopharmaceuticals Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PET Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PET Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PET Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of PET Radiopharmaceuticals in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of PET Radiopharmaceuticals manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PET Radiopharmaceuticals sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
195 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 PET Radiopharmaceuticals Market by Type
- 1.2.1 Global PET Radiopharmaceuticals Market Size by Type, 2020 VS 2024 VS 2031
- 1.2.2 F-18
- 1.2.3 Ru-82
- 1.2.4 Others
- 1.3 PET Radiopharmaceuticals Market by Application
- 1.3.1 Global PET Radiopharmaceuticals Market Size by Application, 2020 VS 2024 VS 2031
- 1.3.2 Neurology
- 1.3.3 Cardiology
- 1.3.4 Oncology
- 1.3.5 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 PET Radiopharmaceuticals Market Dynamics
- 2.1 PET Radiopharmaceuticals Industry Trends
- 2.2 PET Radiopharmaceuticals Industry Drivers
- 2.3 PET Radiopharmaceuticals Industry Opportunities and Challenges
- 2.4 PET Radiopharmaceuticals Industry Restraints
- 3 Global Market Growth Prospects
- 3.1 Global PET Radiopharmaceuticals Revenue Estimates and Forecasts (2020-2031)
- 3.2 Global PET Radiopharmaceuticals Revenue by Region
- 3.2.1 Global PET Radiopharmaceuticals Revenue by Region: 2020 VS 2024 VS 2031
- 3.2.2 Global PET Radiopharmaceuticals Revenue by Region (2020-2025)
- 3.2.3 Global PET Radiopharmaceuticals Revenue by Region (2026-2031)
- 3.2.4 Global PET Radiopharmaceuticals Revenue Market Share by Region (2020-2031)
- 3.3 Global PET Radiopharmaceuticals Sales Estimates and Forecasts 2020-2031
- 3.4 Global PET Radiopharmaceuticals Sales by Region
- 3.4.1 Global PET Radiopharmaceuticals Sales by Region: 2020 VS 2024 VS 2031
- 3.4.2 Global PET Radiopharmaceuticals Sales by Region (2020-2025)
- 3.4.3 Global PET Radiopharmaceuticals Sales by Region (2026-2031)
- 3.4.4 Global PET Radiopharmaceuticals Sales Market Share by Region (2020-2031)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
- 4 Market Competitive Landscape by Manufacturers
- 4.1 Global PET Radiopharmaceuticals Revenue by Manufacturers
- 4.1.1 Global PET Radiopharmaceuticals Revenue by Manufacturers (2020-2025)
- 4.1.2 Global PET Radiopharmaceuticals Revenue Market Share by Manufacturers (2020-2025)
- 4.1.3 Global PET Radiopharmaceuticals Manufacturers Revenue Share Top 10 and Top 5 in 2024
- 4.2 Global PET Radiopharmaceuticals Sales by Manufacturers
- 4.2.1 Global PET Radiopharmaceuticals Sales by Manufacturers (2020-2025)
- 4.2.2 Global PET Radiopharmaceuticals Sales Market Share by Manufacturers (2020-2025)
- 4.2.3 Global PET Radiopharmaceuticals Manufacturers Sales Share Top 10 and Top 5 in 2024
- 4.3 Global PET Radiopharmaceuticals Sales Price by Manufacturers (2020-2025)
- 4.4 Global PET Radiopharmaceuticals Key Manufacturers Ranking, 2023 VS 2024 VS 2025
- 4.5 Global PET Radiopharmaceuticals Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global PET Radiopharmaceuticals Manufacturers, Product Type & Application
- 4.7 Global PET Radiopharmaceuticals Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global PET Radiopharmaceuticals Market CR5 and HHI
- 4.8.2 2024 PET Radiopharmaceuticals Tier 1, Tier 2, and Tier 3
- 5 PET Radiopharmaceuticals Market by Type
- 5.1 Global PET Radiopharmaceuticals Revenue by Type
- 5.1.1 Global PET Radiopharmaceuticals Revenue by Type (2020 VS 2024 VS 2031)
- 5.1.2 Global PET Radiopharmaceuticals Revenue by Type (2020-2031) & (US$ Million)
- 5.1.3 Global PET Radiopharmaceuticals Revenue Market Share by Type (2020-2031)
- 5.2 Global PET Radiopharmaceuticals Sales by Type
- 5.2.1 Global PET Radiopharmaceuticals Sales by Type (2020 VS 2024 VS 2031)
- 5.2.2 Global PET Radiopharmaceuticals Sales by Type (2020-2031) & (K Units)
- 5.2.3 Global PET Radiopharmaceuticals Sales Market Share by Type (2020-2031)
- 5.3 Global PET Radiopharmaceuticals Price by Type
- 6 PET Radiopharmaceuticals Market by Application
- 6.1 Global PET Radiopharmaceuticals Revenue by Application
- 6.1.1 Global PET Radiopharmaceuticals Revenue by Application (2020 VS 2024 VS 2031)
- 6.1.2 Global PET Radiopharmaceuticals Revenue by Application (2020-2031) & (US$ Million)
- 6.1.3 Global PET Radiopharmaceuticals Revenue Market Share by Application (2020-2031)
- 6.2 Global PET Radiopharmaceuticals Sales by Application
- 6.2.1 Global PET Radiopharmaceuticals Sales by Application (2020 VS 2024 VS 2031)
- 6.2.2 Global PET Radiopharmaceuticals Sales by Application (2020-2031) & (K Units)
- 6.2.3 Global PET Radiopharmaceuticals Sales Market Share by Application (2020-2031)
- 6.3 Global PET Radiopharmaceuticals Price by Application
- 7 Company Profiles
- 7.1 Cardinal Health Inc. (U.S.)
- 7.1.1 Cardinal Health Inc. (U.S.) Comapny Information
- 7.1.2 Cardinal Health Inc. (U.S.) Business Overview
- 7.1.3 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.1.4 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
- 7.1.5 Cardinal Health Inc. (U.S.) Recent Developments
- 7.2 Bayer AG (Germany)
- 7.2.1 Bayer AG (Germany) Comapny Information
- 7.2.2 Bayer AG (Germany) Business Overview
- 7.2.3 Bayer AG (Germany) PET Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.2.4 Bayer AG (Germany) PET Radiopharmaceuticals Product Portfolio
- 7.2.5 Bayer AG (Germany) Recent Developments
- 7.3 Nordion, Inc. (Canada)
- 7.3.1 Nordion, Inc. (Canada) Comapny Information
- 7.3.2 Nordion, Inc. (Canada) Business Overview
- 7.3.3 Nordion, Inc. (Canada) PET Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.3.4 Nordion, Inc. (Canada) PET Radiopharmaceuticals Product Portfolio
- 7.3.5 Nordion, Inc. (Canada) Recent Developments
- 7.4 Mallinckrodt plc (Ireland)
- 7.4.1 Mallinckrodt plc (Ireland) Comapny Information
- 7.4.2 Mallinckrodt plc (Ireland) Business Overview
- 7.4.3 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.4.4 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Product Portfolio
- 7.4.5 Mallinckrodt plc (Ireland) Recent Developments
- 7.5 Lantheus Medical Imaging, Inc. (U.S.)
- 7.5.1 Lantheus Medical Imaging, Inc. (U.S.) Comapny Information
- 7.5.2 Lantheus Medical Imaging, Inc. (U.S.) Business Overview
- 7.5.3 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.5.4 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
- 7.5.5 Lantheus Medical Imaging, Inc. (U.S.) Recent Developments
- 7.6 IBA Molecular Imaging (Belgium)
- 7.6.1 IBA Molecular Imaging (Belgium) Comapny Information
- 7.6.2 IBA Molecular Imaging (Belgium) Business Overview
- 7.6.3 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.6.4 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Product Portfolio
- 7.6.5 IBA Molecular Imaging (Belgium) Recent Developments
- 7.7 GE Healthcare (U.K.)
- 7.7.1 GE Healthcare (U.K.) Comapny Information
- 7.7.2 GE Healthcare (U.K.) Business Overview
- 7.7.3 GE Healthcare (U.K.) PET Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.7.4 GE Healthcare (U.K.) PET Radiopharmaceuticals Product Portfolio
- 7.7.5 GE Healthcare (U.K.) Recent Developments
- 7.8 Eczacibasi-Monrol Nuclear Products (Turkey)
- 7.8.1 Eczacibasi-Monrol Nuclear Products (Turkey) Comapny Information
- 7.8.2 Eczacibasi-Monrol Nuclear Products (Turkey) Business Overview
- 7.8.3 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.8.4 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Product Portfolio
- 7.8.5 Eczacibasi-Monrol Nuclear Products (Turkey) Recent Developments
- 7.9 Bracco Imaging S.p.A (Italy)
- 7.9.1 Bracco Imaging S.p.A (Italy) Comapny Information
- 7.9.2 Bracco Imaging S.p.A (Italy) Business Overview
- 7.9.3 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.9.4 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Product Portfolio
- 7.9.5 Bracco Imaging S.p.A (Italy) Recent Developments
- 7.10 Advanced Accelerator Applications S.A. (France)
- 7.10.1 Advanced Accelerator Applications S.A. (France) Comapny Information
- 7.10.2 Advanced Accelerator Applications S.A. (France) Business Overview
- 7.10.3 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.10.4 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Product Portfolio
- 7.10.5 Advanced Accelerator Applications S.A. (France) Recent Developments
- 8 North America
- 8.1 North America PET Radiopharmaceuticals Market Size by Type
- 8.1.1 North America PET Radiopharmaceuticals Revenue by Type (2020-2031)
- 8.1.2 North America PET Radiopharmaceuticals Sales by Type (2020-2031)
- 8.1.3 North America PET Radiopharmaceuticals Price by Type (2020-2031)
- 8.2 North America PET Radiopharmaceuticals Market Size by Application
- 8.2.1 North America PET Radiopharmaceuticals Revenue by Application (2020-2031)
- 8.2.2 North America PET Radiopharmaceuticals Sales by Application (2020-2031)
- 8.2.3 North America PET Radiopharmaceuticals Price by Application (2020-2031)
- 8.3 North America PET Radiopharmaceuticals Market Size by Country
- 8.3.1 North America PET Radiopharmaceuticals Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 8.3.2 North America PET Radiopharmaceuticals Sales by Country (2020 VS 2024 VS 2031)
- 8.3.3 North America PET Radiopharmaceuticals Price by Country (2020-2031)
- 8.3.4 United States
- 8.3.5 Canada
- 9 Europe
- 9.1 Europe PET Radiopharmaceuticals Market Size by Type
- 9.1.1 Europe PET Radiopharmaceuticals Revenue by Type (2020-2031)
- 9.1.2 Europe PET Radiopharmaceuticals Sales by Type (2020-2031)
- 9.1.3 Europe PET Radiopharmaceuticals Price by Type (2020-2031)
- 9.2 Europe PET Radiopharmaceuticals Market Size by Application
- 9.2.1 Europe PET Radiopharmaceuticals Revenue by Application (2020-2031)
- 9.2.2 Europe PET Radiopharmaceuticals Sales by Application (2020-2031)
- 9.2.3 Europe PET Radiopharmaceuticals Price by Application (2020-2031)
- 9.3 Europe PET Radiopharmaceuticals Market Size by Country
- 9.3.1 Europe PET Radiopharmaceuticals Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 9.3.2 Europe PET Radiopharmaceuticals Sales by Country (2020 VS 2024 VS 2031)
- 9.3.3 Europe PET Radiopharmaceuticals Price by Country (2020-2031)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Netherlands
- 10 China
- 10.1 China PET Radiopharmaceuticals Market Size by Type
- 10.1.1 China PET Radiopharmaceuticals Revenue by Type (2020-2031)
- 10.1.2 China PET Radiopharmaceuticals Sales by Type (2020-2031)
- 10.1.3 China PET Radiopharmaceuticals Price by Type (2020-2031)
- 10.2 China PET Radiopharmaceuticals Market Size by Application
- 10.2.1 China PET Radiopharmaceuticals Revenue by Application (2020-2031)
- 10.2.2 China PET Radiopharmaceuticals Sales by Application (2020-2031)
- 10.2.3 China PET Radiopharmaceuticals Price by Application (2020-2031)
- 11 Asia (Excluding China)
- 11.1 Asia PET Radiopharmaceuticals Market Size by Type
- 11.1.1 Asia PET Radiopharmaceuticals Revenue by Type (2020-2031)
- 11.1.2 Asia PET Radiopharmaceuticals Sales by Type (2020-2031)
- 11.1.3 Asia PET Radiopharmaceuticals Price by Type (2020-2031)
- 11.2 Asia PET Radiopharmaceuticals Market Size by Application
- 11.2.1 Asia PET Radiopharmaceuticals Revenue by Application (2020-2031)
- 11.2.2 Asia PET Radiopharmaceuticals Sales by Application (2020-2031)
- 11.2.3 Asia PET Radiopharmaceuticals Price by Application (2020-2031)
- 11.3 Asia PET Radiopharmaceuticals Market Size by Country
- 11.3.1 Asia PET Radiopharmaceuticals Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 11.3.2 Asia PET Radiopharmaceuticals Sales by Country (2020 VS 2024 VS 2031)
- 11.3.3 Asia PET Radiopharmaceuticals Price by Country (2020-2031)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
- 12 South America, Middle East and Africa
- 12.1 SAMEA PET Radiopharmaceuticals Market Size by Type
- 12.1.1 SAMEA PET Radiopharmaceuticals Revenue by Type (2020-2031)
- 12.1.2 SAMEA PET Radiopharmaceuticals Sales by Type (2020-2031)
- 12.1.3 SAMEA PET Radiopharmaceuticals Price by Type (2020-2031)
- 12.2 SAMEA PET Radiopharmaceuticals Market Size by Application
- 12.2.1 SAMEA PET Radiopharmaceuticals Revenue by Application (2020-2031)
- 12.2.2 SAMEA PET Radiopharmaceuticals Sales by Application (2020-2031)
- 12.2.3 SAMEA PET Radiopharmaceuticals Price by Application (2020-2031)
- 12.3 SAMEA PET Radiopharmaceuticals Market Size by Country
- 12.3.1 SAMEA PET Radiopharmaceuticals Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 12.3.2 SAMEA PET Radiopharmaceuticals Sales by Country (2020 VS 2024 VS 2031)
- 12.3.3 SAMEA PET Radiopharmaceuticals Price by Country (2020-2031)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
- 13 Value Chain and Sales Channels Analysis
- 13.1 PET Radiopharmaceuticals Value Chain Analysis
- 13.1.1 PET Radiopharmaceuticals Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 PET Radiopharmaceuticals Production Mode & Process
- 13.2 PET Radiopharmaceuticals Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 PET Radiopharmaceuticals Distributors
- 13.2.3 PET Radiopharmaceuticals Customers
- 14 Concluding Insights
- 15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


